1. Home
  2. PASG vs IRD Comparison

PASG vs IRD Comparison

Compare PASG & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PASG
  • IRD
  • Stock Information
  • Founded
  • PASG 2017
  • IRD 2018
  • Country
  • PASG United States
  • IRD United States
  • Employees
  • PASG N/A
  • IRD N/A
  • Industry
  • PASG Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • PASG Health Care
  • IRD
  • Exchange
  • PASG Nasdaq
  • IRD NYSE
  • Market Cap
  • PASG 42.2M
  • IRD 35.7M
  • IPO Year
  • PASG 2020
  • IRD N/A
  • Fundamental
  • Price
  • PASG $0.52
  • IRD $1.10
  • Analyst Decision
  • PASG Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • PASG 3
  • IRD 1
  • Target Price
  • PASG $8.00
  • IRD $8.00
  • AVG Volume (30 Days)
  • PASG 138.4K
  • IRD 169.0K
  • Earning Date
  • PASG 03-03-2025
  • IRD 03-04-2025
  • Dividend Yield
  • PASG N/A
  • IRD N/A
  • EPS Growth
  • PASG N/A
  • IRD N/A
  • EPS
  • PASG N/A
  • IRD N/A
  • Revenue
  • PASG N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • PASG N/A
  • IRD N/A
  • Revenue Next Year
  • PASG N/A
  • IRD $29.37
  • P/E Ratio
  • PASG N/A
  • IRD N/A
  • Revenue Growth
  • PASG N/A
  • IRD N/A
  • 52 Week Low
  • PASG $0.45
  • IRD $0.81
  • 52 Week High
  • PASG $1.79
  • IRD $2.65
  • Technical
  • Relative Strength Index (RSI)
  • PASG 39.73
  • IRD N/A
  • Support Level
  • PASG $0.52
  • IRD N/A
  • Resistance Level
  • PASG $0.60
  • IRD N/A
  • Average True Range (ATR)
  • PASG 0.05
  • IRD 0.00
  • MACD
  • PASG 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • PASG 20.37
  • IRD 0.00

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: